Longer-Term Outcomes With Single-Agent Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Longer Term Outcomes With Single-Agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: 13-Month Follow-Up From the Pivotal DREAMM-2 Study
Cancer 2021 Jul 27;[EPub Ahead of Print], S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, D Sborov, A Suvannasankha, K Weisel, PM Voorhees, L Womersley, J Baron, T Piontek, E Lewis, J Opalinska, I Gupta, AD CohenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.